Skip to content
2000
  1. Home
  2. A-Z Publications
  3. New Emirates Medical Journal
  4. Volume 5, Issue 1
  5. Article
Volume 5, Issue 1
  • ISSN: 0250-6882
  • E-ISSN: 0250-6882
file format pdf download PDF
side by side viewer icon HTML

Abstract

Background

Disseminated intravascular coagulation (DIC) is a known complication of malignancy. Drug-induced DIC is also reported. Sunitinib is a tyrosine kinase inhibitor approved as an oral targeted therapy in the treatment of different cancers. Here we present a case study of disseminated intravascular coagulation following the administration of Sunitinib after COVID-19 infection in a patient diagnosed with metastatic neuroendocrine tumor of the lung.

Case Report

A 35-year-old male patient with a known metastatic lung neuroendocrine tumor (NET) who was treated with Sunitinib for many years with partial response and tolerating the treatment well-developed recurrent DIC on Sunitinib after COVID-19 infection.

Discussion

COVID-19 infection is reported to be associated with endothelial injury and inflammation. Vascular endothelial growth factor (VEGF) receptors have a role in the protection and modulation of endothelium. Sunitinib is a multikinase inhibitor with anti- VEGF effect. It is possible that endothelial injury after COVID-19 may have triggered recurrent DIC in this patient who had previously tolerated the same drug without problems.

Conclusion

DIC may be underreported especially with antineoplastics having anti-VEGF effects. Potential risk, interaction, and association with COVID-19 infection in the Era of the pandemic are unclear but warrants further research, and drug-induced DIC should be considered in the differential diagnosis of such cases.

© 2024 The Author(s). Published by Bentham Science Publisher.
This is an open access article distributed under the terms of the Creative Commons Attribution 4.0 International Public License (CC-BY 4.0), a copy of which is available at: https://creativecommons.org/licenses/by/4.0/legalcode. This license permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Loading

Article metrics loading...

/content/journals/nemj/10.2174/0250688204666230714110831
2024-01-01
2025-04-24

  • From This Site

    /content/journals/nemj/10.2174/0250688204666230714110831
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
The full text of this item is not currently available.

References

  1. RyanA Disseminated Intravascular CoagulationStat Pearls Publishing2021
     [Google Scholar]
  2. FletcherB. Towards definition, clinical and lab criteria and scoring system for disseminated intravascular coagulation.Thromb. Haemost.20018613271330
     [Google Scholar]
  3. PapageorgiouC. JourdiG. AdjambriE. WalbornA. PatelP. FareedJ. ElalamyI. HoppensteadtD. GerotziafasG.T. Disseminated intravascular coagulation: An update on pathogenesis, diagnosis, and therapeutic strategies.Clin. Appl. Thromb. Hemost.2018249_suppl8S28S10.1177/107602961880642430296833
     [Google Scholar]
  4. ErdemG. DoganM. DemirciN. ZenginN. Oxaliplatin-induced acute thrombocytopenia.J. Cancer Res. Ther.201612250951410.4103/0973‑1482.15405627461601
     [Google Scholar]
  5. BonaventuraA. VecchiéA. DagnaL. MartinodK. DixonD.L. Van TassellB.W. DentaliF. MontecuccoF. MassbergS. LeviM. AbbateA. Endothelial dysfunction and immunothrombosis as key pathogenic mechanisms in COVID-19.Nat. Rev. Immunol.202121531932910.1038/s41577‑021‑00536‑933824483
     [Google Scholar]
  6. GandoS. WadaT. Thromboplasminflammation in COVID-19 coagulopathy: Three viewpoints for diagnostic and therapeutic strategies.Front. Immunol.20211264912210.3389/fimmu.2021.64912234177896
     [Google Scholar]
  7. SmallH.Y. MontezanoA.C. RiosF.J. SavoiaC. TouyzR.M. Hypertension due to antiangiogenic cancer therapy with vascular endothelial growth factor inhibitors: Understanding and managing a new syndrome.Can. J. Cardiol.201430553454310.1016/j.cjca.2014.02.01124786444
     [Google Scholar]
  8. Carrato MenaA. Grande PulidoE. Guillén-PonceC. Understanding the molecular-based mechanism of action of the tyrosine kinase inhibitor: Sunitinib.Anticancer Drugs201021Suppl. 1S3S1110.1097/01.cad.0000361534.44052.c520110785
     [Google Scholar]
  9. New insights into molecular mechanism of sunitinib associated side effects.Mol. Cancer Ther.201110221522223
     [Google Scholar]
  10. Adverse drug reactions associated with sunitinib treatment–characteristics and risk factors. Snezana Mugosa, University of Montenegro.Vojnosanit. Pregl.20217844456461
     [Google Scholar]
  11. Sunitinib Maleate prescribing information Pfizer. Warnings and precautions.2021
     [Google Scholar]
  12. JeY. SchutzF.A.B. ChoueiriT.K. Risk of bleeding with vascular endothelial growth factor receptor tyrosine-kinase inhibitors sunitinib and sorafenib: A systematic review and meta-analysis of clinical trials.Lancet Oncol.2009101096797410.1016/S1470‑2045(09)70222‑019767240
     [Google Scholar]
  13. SonpavdeG. BellmuntJ. SchutzF. ChoueiriT.K. The double edged sword of bleeding and clotting from VEGF inhibition in renal cancer patients.Curr. Oncol. Rep.201214429530610.1007/s11912‑012‑0237‑922532265
     [Google Scholar]
  14. OlivioA. Disseminated intravascular coagulation following administration of Sunitinib.Mol. Clin. Oncol20165121123
     [Google Scholar]
  15. Available at: Lexicomp.com
  16. BonaldoG. Drug-induced disseminated intravascular coagulation: A pharmacovigilance study on the WHO’s database.J. Thromb. Thrombolysis202050476377110.1007/s11239‑020‑02147‑y32445062
     [Google Scholar]
  17. WaddleM. IrvinM. GuptaE. GibbsM. KakarT.S. GannonN.A. ArthursJ.R. FischerD.L. AilawadhiS. Acute disseminated intravascular coagulation after oxaliplatin infusion.Chemotherapy201762529530010.1159/00047184428505615
     [Google Scholar]
/content/journals/nemj/10.2174/0250688204666230714110831
Loading

  • Article Type:     Case Report
Keyword(s): Carcinoma; COVID-19; DIC; Drug; Neuroendocrine; Sunitinib

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test